Per the brand's own landing page, treat the 10,978 and 10,257 figures as brand-reported and unaudited - not confirmed by any outside platform
But you do have to pay attention
Combining the therapeutic approaches of GLP-1 agonists (which target extrahepatic mechanisms for metabolic disorders) with resmetirom (which target intrahepatic mechanisms for MASH and liver fibrosis) seems like a promising strategy for addressing fat accumulation, inflammation, and fibrosis associated with MASH
Rather than slowly cook in the hot water of chronic inflammation, brains on GLP-1 drugs bathe in the cooler climates at which they excel at cognitive functioning
When insureds manage claims within their retention, they tend to focus on preventing losses, handling defense strategically, and resolving matters more quickly